Drug profile · INN
epoetin alfa-epbx
RETACRIT
epoetin alfa-epbx (RETACRIT) is a erythropoietin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — epoetin alfa-epbx
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
epoetin alfa-epbx (RETACRIT) is a erythropoietin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Erythropoietin receptor agonist
Primary target: Erythropoietin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is epoetin alfa-epbx?
epoetin alfa-epbx (RETACRIT) is a erythropoietin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for epoetin alfa-epbx?
RETACRIT is a marketed brand name for epoetin alfa-epbx. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of epoetin alfa-epbx?
epoetin alfa-epbx has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.